{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:14:14Z","timestamp":1790720054497,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T00:00:00Z","timestamp":1268092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00262-010-0831-3","type":"journal-article","created":{"date-parts":[[2010,3,8]],"date-time":"2010-03-08T14:34:30Z","timestamp":1268058870000},"page":"1059-1071","source":"Crossref","is-referenced-by-count":97,"title":["Antitumor activity of Type I and Type III interferons in BNL hepatoma model"],"prefix":"10.1007","volume":"59","author":[{"given":"Walid","family":"Abushahba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugabaskar","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Reuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Raveche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Lasfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei V.","family":"Kotenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,9]]},"reference":[{"key":"831_CR1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","volume":"25","author":"M Sherman","year":"2005","unstructured":"Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25:143\u2013154","journal-title":"Semin Liver Dis"},{"key":"831_CR2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrc1934","volume":"6","author":"PA Farazi","year":"2006","unstructured":"Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674\u2013687","journal-title":"Nat Rev Cancer"},{"key":"831_CR3","first-page":"237","volume":"7","author":"WY Lau","year":"2008","unstructured":"Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7:237\u2013257","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"831_CR4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00534-007-1296-4","volume":"15","author":"A Taketomi","year":"2008","unstructured":"Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y (2008) Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 15:124\u2013130","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"831_CR5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1245\/s10434-007-9559-5","volume":"15","author":"V Mazzaferro","year":"2008","unstructured":"Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG (2008) Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 15:1001\u20131007","journal-title":"Ann Surg Oncol"},{"key":"831_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35\u201343","journal-title":"Lancet Oncol"},{"key":"831_CR7","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMe0807581","volume":"359","author":"M Sherman","year":"2008","unstructured":"Sherman M (2008) Recurrence of hepatocellular carcinoma. N Engl J Med 359:2045\u20132047","journal-title":"N Engl J Med"},{"key":"831_CR8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/PPO.0b013e31816a0fac","volume":"14","author":"CS Georgiades","year":"2008","unstructured":"Georgiades CS, Hong K, Geschwind JF (2008) Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 14:117\u2013122","journal-title":"Cancer J"},{"key":"831_CR9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/hep.510280436","volume":"28","author":"AM Di Bisceglie","year":"1998","unstructured":"Di Bisceglie AM, Carithers RL Jr, Gores GJ (1998) Hepatocellular carcinoma. Hepatology 28:1161\u20131165","journal-title":"Hepatology"},{"key":"831_CR10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/157489208786242296","volume":"3","author":"H Nagai","year":"2008","unstructured":"Nagai H, Sumino Y (2008) Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov 3:220\u2013226","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"831_CR11","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/00004836-200211002-00002","volume":"35","author":"HB El-Serag","year":"2002","unstructured":"El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72\u2013S78","journal-title":"J Clin Gastroenterol"},{"key":"831_CR12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1572-0241.1998.00272.x","volume":"93","author":"G Fattovich","year":"1998","unstructured":"Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K et al (1998) Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 93:896\u2013900","journal-title":"Am J Gastroenterol"},{"key":"831_CR13","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S1542-3565(05)00713-5","volume":"3","author":"M Omata","year":"2005","unstructured":"Omata M, Yoshida H, Shiratori Y (2005) Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 3:S141\u2013S143","journal-title":"Clin Gastroenterol Hepatol"},{"key":"831_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","volume":"46","author":"SM Lin","year":"2007","unstructured":"Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45\u201352","journal-title":"J Hepatol"},{"key":"831_CR15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/135965350601100811","volume":"11","author":"ML Yu","year":"2006","unstructured":"Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF (2006) A sustained virological response to interferon or interferon\/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 11:985\u2013994","journal-title":"Antivir Ther"},{"key":"831_CR16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","volume":"31","author":"JM Llovet","year":"2000","unstructured":"Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodes J, Bruix J (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31:54\u201358","journal-title":"Hepatology"},{"key":"831_CR17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","volume":"245","author":"CM Lo","year":"2007","unstructured":"Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831\u2013842","journal-title":"Ann Surg"},{"key":"831_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8\u201332","journal-title":"Immunol Rev"},{"key":"831_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69\u201377","journal-title":"Nat Immunol"},{"key":"831_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4:63\u201368","journal-title":"Nat Immunol"},{"key":"831_CR21","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","volume":"66","author":"A Lasfar","year":"2006","unstructured":"Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66:4468\u20134477","journal-title":"Cancer Res"},{"key":"831_CR22","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","volume":"176","author":"A Sato","year":"2006","unstructured":"Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176:7686\u20137694","journal-title":"J Immunol"},{"key":"831_CR23","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.4049\/jimmunol.178.8.5086","volume":"178","author":"M Numasaki","year":"2007","unstructured":"Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M (2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178:5086\u20135098","journal-title":"J Immunol"},{"key":"831_CR24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","volume":"44","author":"SE Doyle","year":"2006","unstructured":"Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C et al (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:896\u2013906","journal-title":"Hepatology"},{"key":"831_CR25","doi-asserted-by":"crossref","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","volume":"4","author":"C Sommereyns","year":"2008","unstructured":"Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4:e1000017","journal-title":"PLoS Pathog"},{"key":"831_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/3527608206.ch6","volume-title":"The interferons: characterization and application","author":"SV Kotenko","year":"2006","unstructured":"Kotenko SV, Donnelly RP (2006) Type III IFNs: the Interferon-\u03bb family. In: Meager A (ed) The interferons: characterization and application. Wiley-VCH, Weinheim, pp 141\u2013163"},{"key":"831_CR27","doi-asserted-by":"crossref","first-page":"9822","DOI":"10.1073\/pnas.0610352104","volume":"104","author":"J Huang","year":"2007","unstructured":"Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, Tang S, Silke GV, Putz MM, Smith GL, Kotenko SV (2007) Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci USA 104:9822\u20139827","journal-title":"Proc Natl Acad Sci USA"},{"key":"831_CR28","unstructured":"Kotenko SV (2007) IFN-\u03bbs. In: Zdanov A (ed) Class II cytokines, Transworld Research Network"},{"key":"831_CR29","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1073\/pnas.87.21.8555","volume":"87","author":"XY Fu","year":"1990","unstructured":"Fu XY, Kessler DS, Veals SA, Levy DE, Darnell JEJ (1990) ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci USA 87:8555\u20138559","journal-title":"Proc Natl Acad Sci USA"},{"key":"831_CR30","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.1281555","volume":"258","author":"K Shuai","year":"1992","unstructured":"Shuai K, Schindler C, Prezioso VR, Darnell JEJ (1992) Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258:1808\u20131812","journal-title":"Science"},{"key":"831_CR31","doi-asserted-by":"crossref","first-page":"e1000151","DOI":"10.1371\/journal.ppat.1000151","volume":"4","author":"M Mordstein","year":"2008","unstructured":"Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P (2008) Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4:e1000151","journal-title":"PLoS Pathog"},{"key":"831_CR32","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/JVI.02453-08","volume":"83","author":"D Kugel","year":"2009","unstructured":"Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von MV (2009) Intranasal administration of interferon-alpha reduces seasonal influenza A virus morbidity in ferrets. J Virol 83:3843\u20133851","journal-title":"J Virol"},{"key":"831_CR33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.180.4.2474","volume":"180","author":"N Ank","year":"2008","unstructured":"Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, gnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR (2008) An important role for type III interferon (IFN-lambda\/IL-28) in TLR-induced antiviral activity. J Immunol 180:2474\u20132485","journal-title":"J Immunol"},{"key":"831_CR34","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","volume":"80","author":"N Ank","year":"2006","unstructured":"Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501\u20134509","journal-title":"J Virol"},{"key":"831_CR35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2353\/ajpath.2007.060789","volume":"170","author":"CA Lazaro","year":"2007","unstructured":"Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, Corey L, Coombs RW, Fausto N (2007) Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 170:478\u2013849","journal-title":"Am J Pathol"},{"key":"831_CR36","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887\u20131898","journal-title":"Gastroenterology"},{"key":"831_CR37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.virusres.2007.03.006","volume":"162","author":"SH Hong","year":"2007","unstructured":"Hong SH, Kim K, Shin HJ, Kotenko SV, Park S (2007) The different effect of Interferon-lambda on Hepatitis B Virus replication in two human hepatoma cell lines. Virus Res 162:245\u2013249","journal-title":"Virus Res"},{"key":"831_CR38","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","volume":"79","author":"MD Robek","year":"2005","unstructured":"Robek MD, Boyd BS, Chisari FV (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79:3851\u20133854","journal-title":"J Virol"},{"key":"831_CR39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cyto.2005.04.003","volume":"31","author":"A Meager","year":"2005","unstructured":"Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M (2005) Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 31:109\u2013118","journal-title":"Cytokine"},{"key":"831_CR40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","volume":"7","author":"SG Maher","year":"2008","unstructured":"Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM (2008) IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK\/STAT signaling activity. Cancer Biol Ther 7:1109\u20131115","journal-title":"Cancer Biol Ther"},{"key":"831_CR41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2144\/96216bm10","volume":"21","author":"LA Goldman","year":"1996","unstructured":"Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA (1996) Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques 21:1013\u20131015","journal-title":"Biotechniques"},{"key":"831_CR42","first-page":"4696","volume":"62","author":"JG Segal","year":"2002","unstructured":"Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K (2002) The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target. Cancer Res 62:4696\u20134703","journal-title":"Cancer Res"},{"key":"831_CR43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V83.5.1289.1289","volume":"83","author":"FM Rosenthal","year":"1994","unstructured":"Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B (1994) Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 83:1289\u20131298","journal-title":"Blood"},{"key":"831_CR44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri1684","volume":"5","author":"T Decker","year":"2005","unstructured":"Decker T, Muller M, Stockinger S (2005) The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5:675\u2013687","journal-title":"Nat Rev Immunol"},{"key":"831_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","volume":"25","author":"DB Stetson","year":"2006","unstructured":"Stetson DB, Medzhitov R (2006) Type I interferons in host defense. Immunity 25:373\u2013381","journal-title":"Immunity"},{"key":"831_CR46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/gene.2009.72","volume":"10","author":"K Witte","year":"2009","unstructured":"Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10:702\u2013714","journal-title":"Genes Immun"},{"key":"831_CR47","doi-asserted-by":"crossref","DOI":"10.1002\/3527608206","volume-title":"The interferons: characterization and application","author":"A Meager","year":"2006","unstructured":"Meager A (2006) The interferons: characterization and application. Wiley, Weinheim"},{"key":"831_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","volume":"13","author":"F Belardelli","year":"2002","unstructured":"Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119\u2013134","journal-title":"Cytokine Growth Factor Rev"},{"key":"831_CR49","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1053\/j.seminoncol.2006.10.015","volume":"33","author":"GK bou-Alfa","year":"2006","unstructured":"bou-Alfa GK (2006) Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 33:S79\u2013S83","journal-title":"Semin Oncol"},{"key":"831_CR50","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jhep.2006.01.008","volume":"44","author":"SS Thorgeirsson","year":"2006","unstructured":"Thorgeirsson SS, Lee JS, Grisham JW (2006) Molecular prognostication of liver cancer: end of the beginning. J Hepatol 44:798\u2013805","journal-title":"J Hepatol"},{"key":"831_CR51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.1840170307","volume":"17","author":"CL Lai","year":"1993","unstructured":"Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ (1993) Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17:389\u2013394","journal-title":"Hepatology"},{"key":"831_CR52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","volume":"24","author":"G Fattovich","year":"1996","unstructured":"Fattovich G, Giustina G, Favarato S, Ruol A (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38\u201347","journal-title":"J Hepatol"},{"key":"831_CR53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M et al (1996) Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25:283\u2013291","journal-title":"J Hepatol"},{"key":"831_CR54","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","volume":"26","author":"G Dusheiko","year":"1997","unstructured":"Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26:112S\u2013121S","journal-title":"Hepatology"},{"key":"831_CR55","unstructured":"Lawitz EJ, Zaman A, Muir AJ, Shiffman ML, Yoffe B, Zhang T, Souza S, Hausman DF (2009) Interim results from a phase 1b dose-escalation study of 4\u00a0weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alpha and ribavirin. Abstract 170, 48 edn, p 385A"},{"key":"831_CR56","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105\u20131109","journal-title":"Nat Genet"},{"key":"831_CR57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399\u2013401","journal-title":"Nature"},{"key":"831_CR58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D et al (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100\u20131104","journal-title":"Nat Genet"},{"key":"831_CR59","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O\u2019huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798\u2013801","journal-title":"Nature"},{"key":"831_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133\u2013146","journal-title":"Nat Rev Immunol"},{"key":"831_CR61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1359-6101(03)00043-1","volume":"14","author":"WT Watford","year":"2003","unstructured":"Watford WT, Moriguchi M, Morinobu A, O\u2019Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361\u2013368","journal-title":"Cytokine Growth Factor Rev"},{"key":"831_CR62","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/blood-2008-11-190520","volume":"113","author":"MP Morrow","year":"2009","unstructured":"Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, Weiner DB (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113:5868\u20135877","journal-title":"Blood"},{"key":"831_CR63","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2005-10-4129","volume":"107","author":"FJ Mennechet","year":"2006","unstructured":"Mennechet FJ, Uze G (2006) Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107:4417\u20134423","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0831-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-010-0831-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0831-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T20:07:02Z","timestamp":1685477222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-010-0831-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,9]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s00262-010-0831-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,9]]}}}